Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol

Alain Hendlisz, Amélie Deleporte, Caroline Vandeputte, Nicolas Charette, Marianne Paesmans, Thomas Guiot, Camilo Garcia, Patrick Flamen, Alain Hendlisz, Amélie Deleporte, Caroline Vandeputte, Nicolas Charette, Marianne Paesmans, Thomas Guiot, Camilo Garcia, Patrick Flamen

Abstract

Introduction: Regorafenib was recently approved for patients with pretreated advanced colorectal cancer (aCRC), despite a moderate improvement of the patients' outcome, and significant toxicities. Based on previous studies showing that early fluorodeoxyglucose-positron emission tomography (FDG-PET)-based metabolic response assessment (MRA) might adequately select patients unlikely to benefit from treatment, the RegARd-C trial uses early MRA to identify likely non-responders to regorafenib in a population of patients with aCRC and guide a comprehensive evaluation of genomic and epigenetic determinants of resistance to treatment.

Methods and analysis: RegARd-C is a multicentric prospective study. Its primary objective is to identify non-benefitters from regorafenib given at 160 mg/day, 3 weeks out of 4 in a population of patients with pretreated aCRC. Baseline PET is repeated at day 14 of the first treatment course. MRA is blinded for the investigators. Overall survival (OS) is the primary end point and will be correlated with metabolic parameters and (epi)genetic alterations assessed from tumour and serial blood samples. A target sample size of 105 evaluable patients (70 as derivation set and 35 as validation set), is considered as sufficient to validate an expected HR for OS of metabolic responders compared to metabolic non-responders significantly <1 (with 80% power and 1-sided 5% α in case of a true HR≤0.59 and a responders rate of 47%).

Ethics and dissemination: The study was approved by the Institut Jules Bordet's competent ethics committee and complies with the Helsinki declaration or the Belgian laws and regulations, whichever provides the greatest protection for the patient, and follows the International Conference on Harmonisation E 6 (R1) Guideline for Good Clinical Practice, reference number CPMP/ICH/135/95. The protocol and the trials results, even inconclusive, will be presented at international oncology congresses, and published in peer-reviewed journals. Genomic and epigenetic data will be made available in public open data sets.

Trial registration numbers: EudraCT number: 2012-005655-16; ClinicalTrials.gov number: NCT01929616.

Keywords: CHEMOTHERAPY; NUCLEAR MEDICINE.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
Study design. FDG PET, fluorodeoxyglucose positron emission tomography; FFPE, formalin fixed paraffin embedded; OS, overall survival; PD, disease progression.
Figure 2
Figure 2
Schedule of assessments. FDG PET, fluorodeoxyglucose positron emission tomography; FFPE, formalin fixed paraffin embedded.

References

    1. Parkin DM, Bray F, Ferlay J et al. . Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153–6. 10.1002/ijc.1440
    1. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23:9441–2. 10.1200/JCO.2005.04.4792
    1. Falcone A, Ricci S, Brunetti I et al. . Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670–6. 10.1200/JCO.2006.09.0928
    1. Fuchs CS, Marshall J, Mitchell E et al. . Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779–86. 10.1200/JCO.2007.11.3357
    1. Cassidy J, Tabernero J, Twelves C et al. . XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084–91. 10.1200/JCO.2004.11.069
    1. Van Cutsem E, Peeters M, Siena S et al. . Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658–64. 10.1200/JCO.2006.08.1620
    1. Mross K, Frost A, Steinbild S et al. . A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012;18:2658–67. 10.1158/1078-0432.CCR-11-1900
    1. Strumberg D, Scheulen ME, Schultheis B et al. . Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012;106:1722–7. 10.1038/bjc.2012.153
    1. Grothey A, Van Cutsem E, Sobrero A et al. . Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2012;381:303–12. 10.1016/S0140-6736(12)61900-X
    1. Buyse M, Thirion P, Carlson RW et al. . Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-analysis group in cancer. Lancet 2000;356:373–8. 10.1016/S0140-6736(00)02528-9
    1. Johnson KR, Ringland C, Stokes BJ et al. . Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006;7:741–6. 10.1016/S1470-2045(06)70800-2
    1. Bystrom P, Berglund A, Garske U et al. . Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 2009;20:1057–61. 10.1093/annonc/mdn744
    1. Hendlisz A, Golfinopoulos V, Garcia C et al. . Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol 2012;23:1687–93. 10.1093/annonc/mdr554
    1. Deleporte A, Hendlisz A, Delaunoit T et al. . SoMore trial: combining sorafenib (SOR) with capecitabine (CAP) yields highly encouraging survival results and elevated metabolic response rate in chemorefractory metastatic colorectal cancer (mCRC). Ann Onco 2012;23(Suppl 9):ix178-ix223. doi:10.1093/annonc/mds397
    1. Deleporte A, Hendlisz A, Garcia G et al. . SoMore trial: early metabolic response assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32(suppl 3):524.
    1. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev 2002;2:683–93. 10.1038/nrc882
    1. .

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit